Analysts Offer Predictions for CG Oncology FY2025 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for CG Oncology in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($1.52) per share for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%.

Several other brokerages have also recently commented on CGON. Bank of America reiterated a “buy” rating and set a $65.00 price target on shares of CG Oncology in a research report on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $66.00 target price on shares of CG Oncology in a research report on Friday, December 6th. TD Cowen initiated coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research note on Friday, January 10th. Finally, UBS Group started coverage on CG Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $60.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $63.88.

CG Oncology Trading Up 1.8 %

Shares of CGON stock opened at $30.75 on Thursday. CG Oncology has a 12 month low of $25.77 and a 12 month high of $50.23. The stock has a 50-day moving average price of $30.96 and a 200 day moving average price of $34.11.

Insider Transactions at CG Oncology

In related news, Director Hong Fang Song sold 700,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $28.00, for a total value of $19,600,000.00. Following the completion of the transaction, the director now directly owns 3,003,931 shares of the company’s stock, valued at approximately $84,110,068. This represents a 18.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Leonard E. Post sold 1,000 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The disclosure for this sale can be found here. Insiders have sold a total of 702,000 shares of company stock valued at $19,664,200 over the last 90 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp lifted its stake in CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company’s stock valued at $64,166,000 after acquiring an additional 717,722 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of CG Oncology by 575.7% in the third quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company’s stock valued at $28,149,000 after purchasing an additional 635,653 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of CG Oncology by 96.2% in the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company’s stock worth $40,701,000 after purchasing an additional 528,749 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in CG Oncology by 811.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company’s stock worth $13,687,000 after purchasing an additional 386,000 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in CG Oncology by 153.4% in the third quarter. Wellington Management Group LLP now owns 510,219 shares of the company’s stock valued at $19,251,000 after purchasing an additional 308,852 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.